We're experienced, inventive, energetic and we're looking for partners.
Our existing valuable partnerships boost research excellence and deliver solutions to current industry challenges. We are committed to working with industry, business, government, and the community sector to find innovative solutions to today’s global health problems.
Download our Preferred partner for industry collaboration brochure.
Existing industry partners
In 2014, Associate Professor Justin Hamilton approached Professor Mark Sleeman, Director of the Monash Antibody Technologies Facility (MATF), with a proposal. Associate Professor Hamilton, who heads a lab in Monash’s Australian Centre for Blood Diseases, wanted to use a technology platform MATF had licensed to further his work into a promising anti-thrombotic agent. Find out how a Monash BDI-brokered collaboration with a US biotechnology company, Regeneron Pharmaceuticals, is pushing a Monash discovery to clinical trial.
Monash BDI's Professor Jamie Rossjohn, will lead a three-year research project in collaboration with Janssen Biotech Inc., investigating triggers of the immune-mediated disease psoriasis. Both genetic and environmental factors predispose to the development of psoriasis. Despite the compelling genetic evidence for the triggers of psoriasis there remains an unclear but critical interplay between the two factors. The research project aims to explore this critical interplay and focus on the discovery of potential new treatment approaches to prevent the disease.
Monash University signed a major multiyear research and commercialisation deal with Janssen Biotech Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the early detection and prevention of rheumatoid arthritis, a debilitating autoimmune disease which affects more than 400,000 Australians and more than 24.5 million people worldwide.
Researchers at Monash University and the University of Bristol have created a spin-off biotech company, Cell Mogrify, to turn cells from a patient into tissues and organs needed to treat disease. Funding from a UK angel investment group, will allow Cell Mogrify to provide and test the blueprints for turning cells into specific cells, highly needed in the pharmaceutical industry. This will be used in drug and toxicity testing as well as clinical settings.
Monash Biomedicine Discovery Institute (BDI) and Monash University announced a new research collaboration with the Swiss-based healthcare company Roche (F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.) The collaboration aims to develop next generation treatments for autoimmune diseases, focused on proteins targeting novel molecular pathways.
The Faculty of Medicine, Nursing and Health Sciences at Monash was the first non-USA-based entity to join Pfizer’s Centers for Therapeutic Innovation (CTI) a unique model for academic-industry collaboration, designed to bridge the gap between early scientific discovery and its translation into new medicines.
Monash University announced that it has signed a research collaboration agreement with Janssen-Cilag Pty Ltd., one of the Janssen Pharmaceutical companies of Johnson & Johnson. The collaboration, facilitated by Johnson & Johnson Innovation, Asia Pacific, will focus on ground-breaking research at Monash University to develop potential new medicines to treat autoimmune diseases and disorders.